← SEC 公告列表 | TELO SEC 公告 | Telomir Pharmaceuticals, Inc.（TELO）

重大事件 即時報告 8-K 2026-05-20

Telomir Pharmaceuticals 威爾遜氏症臨床前研究重大突破

於 SEC 網站開啟原文

AI 繁中摘要

🔬 **Telomir Pharmaceuticals 威爾遜氏症臨床前研究重大突破** 日期：2026年5月20日｜申報類型：8-K（監管披露） Telomir Pharmaceuticals（納斯達克代碼：TELO）今日宣佈，其主導候選藥物 **Telomir-1（Telomir-Zn）** 在威爾遜氏症（Wilson’s disease）的臨床前研究結果，已獲國際期刊 *Advances in Redox Research* 以同行評審形式發表。 該研究利用 **ATP7B 缺陷斑馬魚模型** 及細胞系統，評估 Telomir-1 對銅代謝異常引起的氧化壓力、細胞鈣離子失衡及肝臟損傷的治療潛力。結果顯示： - 顯著降低氧化壓力訊號及細胞內鈣離子紊亂 - 減少肝臟銅離子積聚 - 改善肝功能生物標記（肝損傷指標下降） - 逆轉肝臟組織病理學退化 - 提升斑馬魚的游泳運動能力及存活率 管理層表示，這項臨床前證據為 Telomir-1 用於威爾遜氏症（一種罕見遺傳性銅累積疾病）的治療機制提供堅實基礎，並計劃推進後續臨床開發。 🔍 **對投資者的潛在影響** - 正面數據有助增強對 Telomir-1 平台技術的信心，尤其針對氧化應激相關疾病（如神經退化、代謝疾病） - 威爾遜氏症屬孤兒藥領域，若成功獲批，可享有市場獨佔權及加速審批資格 - 惟需注意目前仍處於臨床前階段，臨床試驗結果存在不確定性；是次8-K屬Regulation FD自願披露，不視為正式歸檔 📄 詳細新聞稿內容已作為附件99.1提交。
展開英文正文 
false
 0001971532
 
 
 
 
 
 
 
 0001971532
 
 
 2026-05-20
 2026-05-20
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
D.C. 20549

 

FORM
8-K

 

CURRENT
REPORT

 

Pursuant
to Section 13 or 15(d) of the

Securities
Exchange Act of 1934

 

Date
of Report (Date of earliest event reported): May 20, 2026

 

TELOMIR
PHARMACEUTICALS, INC.

(Exact
Name of Registrant as Specified in its Charter)

 

 
 Florida
 001-41952
  
 87-2606031

 
 (State
 or Other Jurisdiction
  
 (Commission
  
 (IRS
 Employer

 
 of
 Incorporation)
  
 File
 Number)
  
 Identification
 No.)

 

100
SE 2nd St, Suite 2000, #1009

Miami,
Florida 33131

(Address
of Principal Executive Offices)

 

Registrant’s
telephone number, including area code: (786) 396-6723

 

Not
Applicable

(Former
Name or Former Address, if Changed Since Last Report)

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

 

  
 ☐
 Written communications pursuant
 to Rule 425 under the Securities Act (17 CFR 230.425)

  
  
  

  
 ☐
 Soliciting material pursuant
 to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
  
  

  
 ☐
 Pre-commencement communications
 pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  
  
  

  
 ☐
 Pre-commencement communications
 pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title
 of each class
 Trading
 Symbol
 Name
 of each exchange on which registered

 
 Common
 Stock, no par value
  
 TELO
  
 The
 Nasdaq Stock Market LLC

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging
growth company ☒

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

  

 

 

Item
7.01 Regulation FD Disclosure

 

On
May 20, 2026, Telomir Pharmaceuticals, Inc. issued a press release announcing publication of a peer-reviewed
preclinical study titled “Intracellular copper redox modulation disrupts ROS–Ca²⁺ amplification in an ATP7B-deficient
zebrafish model of Wilson’s disease” in the journal Advances in Redox Research.

 

The
publication reported preclinical findings evaluating Telomir-1 (Telomir-Zn) in cellular systems and a zebrafish model of Wilson’s
disease, including findings demonstrating reductions in oxidative stress signaling, intracellular calcium dysregulation, hepatic copper
accumulation, liver injury biomarkers, histopathological degeneration, and improvements in locomotor performance and survival outcomes.

 

In accordance with General
Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any
registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item
9.01 Financial Statements and Exhibits

 

(d)
Exhibits

 

 
 99.1
  
 Press Release dated May 20, 2026

 
 104
  
 Cover
 Page Interactive Data File (embedded within the Inline XBRL document)

 
 

  

  

 

 

SIGNATURES

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

 

  
 TELOMIR
 PHARMACEUTICALS, INC.

  
  
                             

 Dated:
 May 20, 2026
 By:
 /s/
 Erez Aminov

  
 Name:
 Erez
 Aminov

  
 Title:
 Chief
 Executive Officer